Clinical trials: Neoplasms, Advanced Solid
Solid Tumors, CNS Tumors
Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options
This is an open-label, Phase 1/2 multicenter dose escalation study in pediatric patients with relapsed or refractory extracranial solid tumors (Phase 1), with additional expansion cohorts (Phase 2) in patients with primary brain…
- Trial name
- STARTRK-NG (NCT02650401)
- Testing
- Entrectinib
- Where
- 26 sites in United States, Canada and 7 more
- Volunteers
- 69 people
- Sponsor
- Hoffmann-La Roche
Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
Arsenic Trioxide in Treating Patients With Advanced Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of arsenic trioxide in treating patients who have advanced…
- Trial name
- NCT00003630
- Testing
- arsenic trioxide
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Advanced Cancers, Solid Tumors
Erlotinib in Combination With Pralatrexate in Advanced Malignancies
The goal of this clinical research study is to find the highest tolerable dose of the combination of erlotinib and pralatrexate that can be given to patients with advanced cancer.
- Trial name
- NCT01532011
- Testing
- Erlotinib, Pralatrexate
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- M.D. Anderson Cancer Center
Advanced Malignant Solid Neoplasm, Malignant Solid Neoplasm
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
This phase II Pediatric MATCH treatment trial studies how well ensartinib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with ALK or ROS1 genomic alterations that have come back…
- Conditions
- Advanced Malignant Solid Neoplasm, Malignant Solid Neoplasm, Recurrent Ependymoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
- Trial name
- NCT03213652
- Testing
- Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan
- Where
- 126 sites in United States, Australia and 2 more
- Volunteers
- 13 people
- Sponsor
- National Cancer Institute (NCI)
Cancer
Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor
RATIONALE: When irradiated lymphocytes from a donor are infused into the patient they may help the patient's immune system kill cancer cells.
- Trial name
- NCT00161187
- Testing
- therapeutic allogeneic lymphocytes
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
This phase II Pediatric MATCH trial studies how well erdafitinib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with FGFR mutations that have spread to other places in the body and…
- Conditions
- Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma, Recurrent Childhood Malignant Germ Cell Tumor, Recurrent Childhood Medulloblastoma
- Trial name
- NCT03210714
- Testing
- Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan
- Where
- 116 sites in United States, Puerto Rico
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma
Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
This phase II Pediatric MATCH trial studies how well samotolisib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with TSC or PI3K/MTOR mutations that have spread to other places in the…
- Conditions
- Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Malignant Glioma
- Trial name
- NCT03213678
- Testing
- Biospecimen Collection, Computed Tomography, FDG-Positron Emission Tomography
- Where
- 127 sites in United States, Puerto Rico
- Volunteers
- 18 people
- Sponsor
- National Cancer Institute (NCI)
Liver Cancer, Advanced Solid Tumors
Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, Leucovorin, and Avastin
PRIMARY: To determine the toxicity and tolerability of intra-arterial hepatic oxaliplatin every three weeks administered in combination with systemic intravenous Fluorouracil, Leucovorin and bevacizumab to patients with advanced…
- Trial name
- NCT00507585
- Testing
- Fluorouracil, Avastin, Leucovorin
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- M.D. Anderson Cancer Center
Stage IV Breast Cancer, Stage IV Pancreatic Cancer
Prospective Cohort Study Depending on the Use of Palliative Care for Advanced Stage of Cancer Patients
This study evaluates the change of quality of life, treatment decision and utilization of health care depending on the use of palliative care in advanced cancer patients by a prospective cohort study.
- Conditions
- Stage IV Breast Cancer, Stage IV Pancreatic Cancer, Stage IV Colon Cancer, Stage IV Gastric Cancer
- Trial name
- NCT03222258
- Testing
- Early palliative care, Routine hospice care
- Where
- 15 sites in South Korea
- Volunteers
- 444 people
- Sponsor
- Seoul National University Hospital
Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
This phase II Pediatric MATCH screening and multi-sub-trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have…
- Conditions
- Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Histiocytic Sarcoma
- Trial name
- NCT03155620
- Testing
- Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration and Biopsy
- Where
- 172 sites in United States, Australia and 2 more
- Volunteers
- 1,377 people
- Sponsor
- National Cancer Institute (NCI)
Neoplasm
A Study to Test Different Doses of BI 891065 Alone and in Combination With BI 754091 in Asian Patients With Different Types of Advanced Cancer (Solid Tumours)
The primary objective of this trial is: Part A To determine the Maximum tolerated dose (MTD) and/or the recommended dose (RD) of BI 891065 monotherapy for further development in Asian patients with advanced solid tumours Part B…
- Trial name
- NCT04138823
- Testing
- BI 891065
- Where
- Japan
- Volunteers
- 12 people
- Sponsor
- Boehringer Ingelheim
Advanced Cancer
Latent Tuberculosis Infection in Cancer Patients
Primary Objective: 1. To evaluate the performance of the new T-SPOT.TB test and the conventional TST for screening of Latent Tuberculosis infections in patients with cancer and those undergoing Hematopoietic Stem Cell Transplant.
- Trial name
- NCT00507754
- Testing
- T-SPOT TB test
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- M.D. Anderson Cancer Center
Advanced Cancers
Study of Vemurafenib, Carboplatin, and Paclitaxel
The goal of this clinical research study is to find the highest tolerable dose of vemurafenib that can be given in combination with carboplatin and paclitaxel patients with advanced cancer.
- Trial name
- NCT01636622
- Testing
- Vemurafenib, Carboplatin, Paclitaxel
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- M.D. Anderson Cancer Center
Advanced Gastric Adenocarcinoma
Phase Ib, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel, in Any Solid Cancer and Sequential Phase II, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel in Advanced Gastric Adenocarcinoma Patients With MET Amplification as a Second Line Treatment
Phase Ib/II, single-arm study of AZD6094 (Volitinib) in combination with docetaxel, in advanced gastric adenocarcinoma patients with MET amplification as a second-line treatment.
- Trial name
- NCT02447406
- Testing
- AZD6094, docetaxel
- Where
- South Korea
- Volunteers
- 7 people
- Sponsor
- Samsung Medical Center
Triple-Negative Breast Cancer, High-grade Serous Ovarian Cancer
Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid Tumors
This is a Phase I, open-label, multi-center trial designed to evaluate the safety, tolerability and pharmacokinetics of CUDC-907 administered orally to subjects with advanced/relapsed solid tumors.
- Conditions
- Triple-Negative Breast Cancer, High-grade Serous Ovarian Cancer, Solid Tumors, NUT Midline Carcinoma
- Trial name
- NCT02307240
- Testing
- CUDC-907
- Where
- 4 sites in United States
- Volunteers
- 43 people
- Sponsor
- Curis, Inc.
Solid Tumors
A Study of Ridaforolimus in Pediatric Participants With Advanced Solid Tumors (MK-8669-056)
The main objectives of this trial are to determine the recommended dose of ridaforolimus for pediatric participants with advanced solid tumors by measuring the number of participants experiencing dose-limiting toxicities (DLTs)…
- Trial name
- NCT01431534
- Testing
- Ridaforolimus
- Volunteers
- 20 people
- Sponsor
- Merck Sharp & Dohme LLC
Advanced Solid Tumor
LIONS (PLK4 Inhibitor in Advanced Solid Tumors)
The primary objective of this study is to identify a safe and tolerated dose and schedule of the orally administered PLK4 inhibitor RP-1664.
- Trial name
- NCT06232408
- Testing
- RP-1664
- Where
- 5 sites in United States, Denmark
- Volunteers
- 29 people
- Sponsor
- Repare Therapeutics
Advanced Solid Tumors Cancer, Hospitalizations
Biological Age Predicts 90-Day Mortality in Advanced Cancer
This retrospective study evaluates whether biological age, calculated using the PhenoAge model, predicts short-term outcomes in patients with advanced cancer who were hospitalized.
- Trial name
- BIOAGE-CAN (NCT07035470)
- Testing
- PhenoAge-Based Biological Age Assessment
- Where
- Turkey (Türkiye)
- Volunteers
- 1,615 people
- Sponsor
- Ankara Etlik City Hospital
Brain and Central Nervous System Tumors, Gastrointestinal Carcinoid Tumor
Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors
RATIONALE: Radiolabeled octreotide can locate tumor cells and deliver radioactive tumor-killing substances to them without harming normal cells.
- Conditions
- Brain and Central Nervous System Tumors, Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Neuroblastoma
- Trial name
- NCT00049023
- Testing
- 90Y-DOTA-tyr3-OCTREOTIDE
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- O'Dorisio, M S
Solid Tumor, Osteosarcoma
Metronomic Chemotherapy in Patients With Advanced Solid Tumor With Bone Metastasis and Advanced Pretreated Osteosarcoma
This is a prospective open-labeled phase I trial based on a dose escalating study design assessing two dose levels of sirolimus when prescribed in combination with metronomic cyclophosphamide (CP), methotrexate (MT) and…
- Trial name
- METZOLIMOS (NCT02517918)
- Testing
- Sirolimus combined with CP, MT and ZA
- Where
- 3 sites in France
- Volunteers
- 23 people
- Sponsor
- Institut Bergonié